Due to different economic systems, historical traditions, market environment, legal concepts and other conditions, the patterns of biopharmaceutical enterprises corporate governance varies. This paper aims to prompt developed countries to draw on their strengths to encourage developing countries towards the introduction of governance and management practices in biopharmaceutical enterprises better serving socioeconomic development, following the examples of market-oriented company governance seen in U.K. and U.S. companies as well as the bank-oriented models of Japanese and German companies.